Social Links

Follow on Facebook Follow on TwitterFollow EiR on PinterestFollow EiR on Instagram

Xpert Access

×

Login To Get Involved!


Forgot your username?


Forgot your password?

×

Join Us At EiR Now!

DNRS Roof Banner

 

DNRS Interactive DVD Series & Seminars

Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome

 

 

 

 

World J Gastroenterol. 2008 Aug 28;14(32):5020-4.

 

Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome.

 

Barrett JS, Canale KE, Gearry RB, Irving PM, Gibson PR. Monash University, Department of Medicine, and Department of Gastroenterology, Box Hill Hospital, Box Hill, Victoria 3128, Australia. This email address is being protected from spambots. You need JavaScript enabled to view it..

 

 

AIM: To determine whether Lactobacillus casei strain Shirota (Yakult(R)) can alter small intestinal bacterial overgrowth (SIBO), as tested by the lactulose breath test, and whether this is associated with changes in symptoms in irritable bowel syndrome (IBS).

 

METHODS: 18 patients with IBS (Rome II criteria), who showed an early rise in breath hydrogen with lactulose (ERBHAL), consumed 65 mL of Yakult(R) daily for 6 wk. Lactulose breath test was repeated at the end of the treatment period. Symptoms were recorded daily using a 10 cm visual analogue scale.

 

RESULTS: 14 patients completed the study, 9 (64%) had reversal of ERBHAL, with the median time of first rise in breath hydrogen increasing from 45 to 75 min (P = 0.03). There was no significant improvement in the symptom score with probiotic therapy, except for wind (P = 0.04). Patients commencing with at least moderate symptoms and who no longer had ERBHAL at the end of treatment, showed improvement in the overall symptoms scores [median final score 5.3 (IQR 3.9-5.9), 55% reduction; n = 6] to a greater extent than those who had had persisting ERBHAL [final score 6.9 (5.0-7.0), 12% reduction; n = 5; P = 0.18].

 

CONCLUSION: Yakult(R) is effective in altering fermentation patterns in the small bowel, consistent with reducing SIBO. The loss of ERBHAL was associated with reduced symptoms. The true interpretation of these findings awaits a randomised, controlled trial.

 

PMID: 18763284 [PubMed - in process]

 

 

 

{mosgoogle}

 

{mos_sb_discuss:11}

 


 

 

Related Articles:

 

Home Testing & Sanitizer:
 

 

 

 

 

ADVERTISEMENT

 

  • No comments found

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner